This is an interesting analysis for a critical workflow in biopharma/biotherapeutics!
It's applicable in other places, but where this is used the most is when an antibody drug is manufactured in a hamster ovary cell line or something and you need to make sure that not much is going along for the ride.
In this case, do our algorithms designed for deep global analysis make the cut? In the end it looks like they all do pretty well (Figure 5 is a great summary) though some are clearly better than others. One commercial package I wasn't even aware of somehow (Byos, from ProteinMetrics) actually has a specific workflow for host cell proteins - and you can imagine if they were thinking about that during the design they'd do a good job - and that does seem to be the case.
No comments:
Post a Comment